Outcome of Board Meeting

Date: 17 July 2026 Ref. No.: TCPCL/SEC/2026-27/00021 The General Manager, The Manager, Corporate relationship department, Listing department, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Fort, Bandra-Kurla Complex, Bandra(E), Mumbai-400 001 Mumbai-400 051 Scrip Code: 543321 Scrip Symbol: TATVA Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Dear Sir/Madam, Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Tatva Chintan Pharma Chem Limited (the "Company") at its meeting held today i.e. 17 July 2026 have inter-alia, approved and taken on record the following items: 1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30 June 2026. In this regard, please find enclosed: i. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30 June 2026; and ii. Limited Review Report (Standalone and Consolidated) for the quarter ended 30 June 2026, issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company. 2. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Chintan Nitinkumar Shah (DIN: 00183618) designated as Managing Director of the Company, liable to retire by rotation, for a further period of three (3) years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company. 3. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Ajaykumar Mansukhlal Patel (DIN: 00183745) designated as Whole-time Director of the Company, liable to retire by rotation, for a further period of three (3) years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company. 4. The Board, based on the recommendation of Nomination and Remuneration Committee, has approved the re-appointment of Mr. Shekhar Rasiklal Somani (DIN: 00183665) designated as Whole-time Director of the Company, liable to retire by rotation, for a further period of three (3) years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the Members at the ensuing Annual General Meeting of the Company. 5. The Board has approved the proposed capacity expansion (addition) of manufacturing capacities of various specialty chemicals at the new greenfield unit at Dahej - III, Dahej Industrial Estate, Taluka: Vagra, District: Bharuch, Gujarat, India. As part of our growth strategy, the new manufacturing facility (unit) will further strengthen the Company’s infrastructure and help to meet growing market demands. 6. The Board has approved the proposal for increase in the borrowing limits of the Company pursuant to Section 180(1)(c) of the Companies Act, 2013, from Rs. 300,00,00,000 (Rupees Three Hundred Crores only) to Rs. 1,000,00,00,000 (Rupees One Thousand Crores only), subject to approval of the Members at the ensuing Annual General Meeting of the Company. Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January 2026 for the matters mentioned at Item 2, 3, 4, and 5 above, is enclosed herewith as “Annexure A”. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Meeting commenced at 11:30 A.M. and concluded at 03:40 P.M. Kindly take above intimation on your record and oblige. Thanking you, Yours faithfully, For Tatva Chintan Pharma Chem Limited Ishwar Nayi Company Secretary and Compliance Officer M. No.: A37444 Encl.: As above Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January 2026. Annexure A Sr. Particulars Mr. Chintan Nitinkumar Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal No. Shah Patel Somani (Managing Director) (Whole-time Director) (Whole-time Director) 1. Reason for change Re-appointment of Mr. Chintan Re-appointment of Mr. Re-appointment of Mr. viz. appointment, Nitinkumar Shah (DIN: Ajaykumar Mansukhlal Patel Shekhar Rasiklal Somani re-appointment, 00183618) as Managing Director (DIN: 00183745) as (DIN: 00183665) as resignation, removal, of the Company Whole-time Director of the Whole-time Director of the death or otherwise Company Company 2. Date of appointment / Date of re-appointment: 01 Date of re-appointment: 01 Date of re-appointment: 01 re-appointment / February 2027 February 2027 February 2027 cessation (as applicable) & term of Re-appointment for a further Re-appointment for a further Re-appointment for a further appointment / period of three (3) years from 01 period of three (3) years from 01 period of three (3) years from re-appointment February 2027 to 31 January 2030 February 2027 to 31 January 2030 01 February 2027 to 31 January (both days inclusive), subject to (both days inclusive), subject to 2030 (both days inclusive), the approval of the members of the approval of the members of subject to the approval of the the Company the Company members of the Company His present tenure as Managing His present tenure as Whole-time His present tenure as Director will conclude on 31 Director will conclude on 31 Whole-time Director will January 2027 January 2027 conclude on 31 January 2027 3. Brief profile (in case Mr. Chintan Nitinkumar Shah, Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani, of appointment) aged 53, is a Bachelor of Patel, aged 54, is a Bachelor of aged 52, is a Bachelor’s Engineering (Computer Engineering (Chemical). He is degree in pharmacy. He is one Science). He is one of the one of the founding members of the founding members and founding members and and promoters of Tatva Chintan promoters of Tatva Chintan promoters of Tatva Chintan Pharma Chem Limited. He Pharma Chem Limited. He Pharma Chem Limited. He joined the Company in the year joined the Company in the joined the Company in the year 1996. He has over 31 years of year 1996. He has over 30 1996. He has over 30 years of experience in the manufacturing years of experience in the experience in the manufacturing / specialty chemical industry. manufacturing / specialty / specialty chemical industry. He holds following position in chemical industry. He holds following position in the subsidiary of the Company. He holds following position the subsidiary of the Company. Tatva Chintan USA Inc. - in the subsidiary of the Tatva Chintan USA Inc. - Director and Treasurer Company. President and Director Tatva Chintan Europe B.V. - Tatva Chintan USA Inc. - Tatva Chintan Europe B.V. - Board Member Director and Secretary Board Member Tatva Chintan Europe B.V. - Board Member 4. Disclosure of Mr. Chintan Nitinkumar Shah is Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani Relationship between not related to any of the Patel is not related to any of the is not related to any of the Directors (in case of Directors of the Company Directors of the Company Directors of the Company appointment as a Director) 5. Information as Mr. Chintan Nitinkumar Shah is Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani required pursuant to not debarred from holding the Patel is not debarred from is not debarred from holding BSE Circular with ref. office of Director by virtue of holding the office of Director the office of Director by no. any SEBI Order or any other by virtue of any SEBI Order or virtue of any SEBI Order or LIST/COMP/14/2018 such Authority [Showing first 8,000 characters — download PDF for full document]